Assess Pharmacokinetics, Safety and Tolerability in Healthy Chinese Volunteers After Oral Doses of Saxagliptin
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Saxagliptin is a new investigational medication being developed for treatment of type 2
diabetes. This Phase I study is designed to assess the pharmacokinetics of saxagliptin and
its pharmacologically active metabolite, BMS-510849, following single and multiple oral doses
of 5 mg saxagliptin in healthy Chinese subjects.